In general, RUNX1‐RUNX1T1‐positive AML is a core‐binding factor AML for which high‐dose cytarabine is effective as consolidation therapy [15], but the usefulness of allo‐HSCT in first CR has not been demonstrated. This evidence concerns the gene RUNX1 and acute myeloid leukemia.